Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/28/2025 | $15.00 | Overweight | Stephens |
| 9/3/2025 | $7.00 | Buy → Neutral | BofA Securities |
| 6/30/2025 | $23.00 | Buy | H.C. Wainwright |
| 2/20/2025 | $25.00 | Buy | Citigroup |
| 2/19/2025 | $20.00 | Buy | Canaccord Genuity |
| 2/7/2025 | $15.00 | Buy | BofA Securities |
| 12/2/2022 | $11.00 | Buy | H.C. Wainwright |
| 11/19/2021 | $18.00 | Outperform | BMO Capital |
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and CEO, will present the phase 3 clinical trial of CAN-2409 in newly diagnosed, localized prostate cancer, which achieved its primary endpoint, supported by secondary endpoints Poster presentation: Daniel Sterman M.D., Professor at NYU Langone Health will present ‘Multi-omics analysis of CAN-2409 in non-small cell lung cancer (NSCLC) identifies immune signatures distinguishing response patterns in non-squamous subtypes, offering new insights into mechanisms of tumor response'Poster presentation: Anne Diers, Ph.D., Vice Presiden
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom. Presentation Details: Date: Tuesday, November 18, 2025Time: 8:00-8:25 AM GMT / 4:00-4:25 AM ETWebcast Link: Jefferies / Candel Presentation A webcast of the presentation will be available by selecting Events and Pres
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00
BofA Securities downgraded Candel Therapeutics from Buy to Neutral and set a new price target of $7.00
H.C. Wainwright resumed coverage of Candel Therapeutics with a rating of Buy and set a new price target of $23.00
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
EFFECT - Candel Therapeutics, Inc. (0001841387) (Filer)
8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel's Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 f
NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Charles Schoch as Chief Financial Officer (CFO). Mr. Schoch, who has served as interim CFO of Candel since January 2024, will transition to the CFO role permanently, effective immediately. "Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "He has effectively
NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Company's positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. The discussion will follow Dr.
Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancerThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identifiedThe phase 3 clinical trial was conducted under a Special Protocol Assessment (SPA) with the FDA NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients
Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "Our 2022 achievements reaffirm our belief that using our viral immunotherapies to mobilize the patient's immune system to fight cancer represents a promising a
SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)
SC 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)
SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)